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ABSTRACT 
Atherosclerosis, an inflammatory disease, is the major cause of cardiovascular disease - the 
main cause of death worldwide. T cells are central orchestrators of inflammation in 
atherosclerosis and critically depend on costimulation for adequate function. Hence, 
costimulation is pivotal for maintaining immunological homeostasis of inflammatory 
responses, and a dysregulated immune response may aggravate inflammation in 
atherosclerosis. Costimulators are therefore of central interest in the pathogenesis of 
cardiovascular disease. CD137 and OX40 ligand are important costimulatory molecules of 
the tumor necrosis factor superfamily, but their role in vascular inflammation has been 
unclear.  
We used human biobanks and clinical cohorts in combination with experimental models of 
atherosclerosis and atherothrombosis to investigate the involvement of CD137 and 
OX40 ligand in the pathogenesis of cardiovascular disease. 
We observed that CD137 was expressed in human and murine atherosclerosis, and that 
activation of CD137 promotes inflammation and atherosclerosis development in 
hypercholesterolemic mice. By studying gene expression in cell lines, we found an 
association between the single nucleotide polymorphism (SNP) rs2453021 and CD137 
mRNA expression in human lymphoid cells. The minor allele of this SNP was associated 
with an increased intima media thickness in human carotid arteries in individuals with risk 
factors of cardiovascular disease. To study the influence of CD137 activation on 
atherothrombosis, we turned to an experimental plaque rupture model. We observed that 
CD137 mRNA expression was higher in ruptured compared to non-ruptured murine carotid 
lesions. Stimulation of CD137 promoted vascular and systemic inflammation, but did not 
increase plaque rupture frequency.  
Others have reported an association between the SNP rs3850641 in OX40 ligand and 
cardiovascular risk. We did observe expression of OX40 ligand on endothelial cells within 
human carotid atherosclerotic lesions, and the OX40 ligand expression was induced by tumor 
necrosis factor (TNF) in cultured vascular endothelial cells. However, we found no 
association with the risk for stroke in two independent populations. 
In conclusion, the studies in this thesis demonstrate expression of CD137 and OX40 ligand in 
human atherosclerotic lesions, and that activation of CD137 promotes inflammation and 
atherosclerosis development in hypercholesterolemic mice. These new insights on the 
pathophysiology of atherosclerosis warrant further studies of the therapeutic potential of 
interventions in costimulation for treatment of cardiovascular disease. 
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1 INTRODUCTION – A NEED FOR NEW DISCOVERIES! 
Inventions and development are critically dependent on new discoveries and, perhaps 
sometimes, novel ways of looking at old discoveries. By using the enormous amounts of 
existing knowledge, we can use new technical tools to look at old problems with better 
resolution, or develop new concepts that makes us view problems in a completely novel way. 
Pre-clinical laboratory research is frequently done in a milieu far away from the patients 
struck by an acute life-threatening disease. In the clinic, far from the laboratory, we still lack 
adequate methods to predict, identify, and treat patients with the disease that is the most 
common cause of death globally – cardiovascular disease. Even though the patients receive 
state of the art medical treatments, and get the best possible care by dedicated doctors and 
nurses, the suffering of patients and the persons close to the affected patients is still immense. 
To get maximum benefit from the joint efforts and expertise, the need for a mutual interface 
between the experimental and clinical branches of cardiovascular research becomes more 
evident as the complexity of atherosclerosis unravels. Since the underlying mechanisms of 
cardiovascular disease are not fully known, the endeavor for cure and prevention is yet to be 
completed, and the road ahead is doubtlessly bordered by novel discoveries.  
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2 AIMS 
The overall aim of this thesis was to determine the roles of the costimulatory molecules 
CD137 and OX40 ligand in atherosclerosis and cardiovascular disease. 
 
The specific aims were to: 
 
• investigate CD137 expression in atherosclerosis and determine whether activation of 
CD137 aggravates disease 
 
• investigate genetic influence on human CD137 expression and its association with 
cardiovascular disease 
 
• determine whether CD137 activation promotes rupture of atherosclerotic plaques 
 
• describe OX40 ligand expression in human atherosclerotic lesions and determine 
whether the minor allele of rs3850641 in OX40 ligand is associated with increased 
risk for stroke 
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3 A COSTIMULATORY PERSPECTIVE ON THE IMMUNE 
SYSTEM 
The immune system is vital for the survival of all human beings. A constant battle against 
external and internal pathogens is normal. The battle is fought by immune cells and is 
regulated by receptors that detect danger, by cytokines, cell-cell interactions, neural reflexes 
and more. Immune cells with well-defined specificities and functions interact to optimize 
homeostasis and promote health. Often, macrophages and dendritic cells (DC) phagocytose 
infected and damaged tissue, and present fragments i.e. antigens, to the central orchestrators 
of immune responses, T cells. If a T cell recognizes a dangerous fragment, for example a 
piece of a known microbe, it does not run ahead to immediate war. Instead, it stops and 
awaits a “go-signal” or a “stop-signal” from the immune cell presenting the antigen. This is a 
key feature of the immune response that protects from senseless over-activation of the very 
powerful T cells, and ensures that the response to threat will be adequately measured. These 
control signals are called “costimulatory” or “coinhibitory” and are performed by so called 
costimulatory and coinhibitory receptors and ligands (Figure 1). The costimulatory molecules 
have emerged as key players in an adequate functional immune response. Their importance is 
underscored by their functionality as pivotal on- or off-buttons for the cellular immune 
response. In addition, costimulation is essential for fine-tuning of the inflammatory response 
[1, 2] and has been widely studied in the context of the acquired, so called adaptive, immune 
response [3].  
  
Figure 1. Costimulation and coinhibition of T cells. Both T cell antigen recognition and 
costimulation is needed for activation of T cells. Coinhibition or lack of costimulation 
promote anergy or apoptosis of the T cell. Definitions are in the list of abbreviations. 
Activated T cells
APC T cell
T cell receptor complex
MHC + Antigen
Costimulation
Coinhibition
Immature/unactivated 
APC
Anergy
Apoptotic T cells
Anergy
Apoptotic T cells
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The most well-characterized costimulatory and coinhibitory molecules are of the CD28/B7 
family, and the costimulatory molecules of the tumor necrosis factor superfamily (TNFSF), 
which include CD137, CD137 ligand (CD137L), OX40 and, OX40 ligand (OX40L). 
The CD28/B7 pathway is prototypical for costimulation. CD28 is expressed on T cells and is 
the receptor for the classical “signal 2” which provides the “go ahead” for T cells that have 
recognized an antigen (“signal 1”). The B7 family molecules B7-1 (CD80) and B7-2 (CD86) 
ligate CD28 resulting in costimulation. The B7-1 and B7-2, may also ligate the cytotoxic T-
lymphocyte-associated antigen 4 (CTLA4) (CD152) providing an inhibitory signal balancing 
the response. 
3.1 COSTIMULATION OF T CELLS 
T cells recognize antigens presented on major histocompatibility complex (MHC) molecules 
by specialized antigen presenting cells (APC), including macrophages, DC and B cells. 
T cells occur in a number of varieties, including CD4+ helper T cells, which also support 
B cell function, and CD8+ cytotoxic T cells, which kill infected or transformed cells [3]. 
CD4+ T helper cells recognize antigens presented on MHC class II molecules by APCs. The 
adaptive response is fine-tuned by costimulatory signals, and lack of costimulation in T cells 
results in T cell anergy or apoptosis [4] (Figure 1). T cell expression of the costimulatory 
molecule CD137 is not ubiquitous, but occurs on subgroups of CD4+ T cells and on CD8+ 
T cells, and is mostly associated with activation [1] (see also Table 1). Hence, presence or 
absence of CD137 and its ligand can determine the fate, anergy/apoptosis or 
activation/proliferation, of particular T cells in an immune response. Furthermore, effects of 
costimulation may also differ between effector T cell subsets. This is exemplified by CD137 
that has a preference for controlling CD8+ T cell response [5, 6]. 
Regulatory T cells (Treg) include the CD4+CD25+Foxp3+ subpopulation. Treg are essential 
for maintaining immunological homeostasis and for controlling immunological tolerance. 
Mice deficient in Treg develop an autoimmune phenotype [7]. Costimulatory factors play a 
key role in Treg biology. For example, ligation of CD137 expressed on Treg results in 
proliferation, which may suppress immune responses [8, 9]. Interestingly, ligation of OX40 
by OX40L can inhibit the conversion of naïve T cells into Foxp3+ Treg, and suppress the 
TGFβ driven Foxp3+ development [10]. Hence, costimulatory molecules of the TNFSF can 
have opposite effects on Treg. Thus, costimulation of T cells through members of the 
TNFRSF can either promote or inhibit Treg development, and fine-tune an ongoing 
inflammatory response in intricate ways that as of yet are only partly understood. 
Coinhibitory signals are negative regulators of T cell responses and coinhibitory receptors 
partly share ligands with the costimulatory receptors. Hence, the timing, balance and spatial 
distribution of costimulatory and coinhibitory receptor and ligand expression can exert 
pivotal effects on T cell activation and on important aspects of the immune response. 
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3.2 COSTIMULATION BEYOND T CELLS 
Interestingly, there are a growing number of reports that support a vital role for costimulatory 
molecules also in the inborn, so called innate, immune response. For example, CD137 
deficient mice are resistant to endotoxemic shock, a model of severe, acute septicemia [11]. 
Moreover, CD137 deficient mice have fewer natural killer (NK) cells, key cells for the innate 
defense against viral infection and tumor formation. In fact, most cells of the innate 
immunity, such as macrophages, express and respond to signals through costimulatory and 
coinhibitory molecules [3]. Furthermore, OX40L, expressed on APCs and ECs play a role in 
the neo-formation of microvessels in atherosclerotic lesions, a process involving several cell 
types [12]. Cells known to express the TNFSF members CD137, CD137L, and OX40L are 
listed in table 2.  
3.3 A STIMULATORY CONCLUSION 
Considering the crucial importance of costimulation in adaptive and innate immunological 
homeostasis, it is not surprising that manipulation of costimulatory molecule activity has a 
significant impact in a number of experimental inflammatory diseases. For example, in 
models of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and 
atherosclerosis, manipulation of costimulation lead to profound effects on inflammation and 
disease [12-14]. Both the innate and the adaptive immune systems are essential for host 
defense and for tissue repair, and it has become more evident that the cross talk between 
innate and adaptive immunity is a crucial function for the immune system as a whole. 
Costimulation is pivotal for maintaining immunological homeostasis, and a dysregulated 
immune response may result inflammatory diseases, among them atherosclerosis. 
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Table 1. T cell subsets relevant for CD137 
     Inducing 
cytokines 
Typical 
cytokines 
Effect in 
atherosclerosis 
Effect of CD137 ligation Reference 
        Helper T cells 
(CD4+)  
   
  Th1 IFNγ, IL-12 IFNγ, TNF, 
IL-2 
Pro-inflammatory Activation, proliferation, 
prolonged survival 
Szabo et al. 2000[15]; Mosman et al. 
1986[16] 
  Th2 IL-4, IL-33 IL-4, IL-5, 
IL-13 
Unclear Activation, proliferation, 
prolonged survival 
Zheng et al. 1997[17] 
  Th17 IL-6, TGFβ IL-17 Unclear (pro-
atherosclerotic and 
athero-protective) 
Inhibits generation of 
Th17 cells 
Ivanov et al. 2006[18]; Veldhoen et al. 
2006[19]; Kim Choi et al. 2011[20]; 
Gisterå et al. 2013[21] 
  Treg IL-2, TGFβ TGFβ, IL-10, 
IL-35 
Athero-protective Proliferation, more de Boer et al. 2007[22]; Klingenberg et al. 
2013[23]; Mallat et al. 2003[24] 
        Cytotoxic T cells 
(CD8+) 
 - IFNγ, TNF, 
IL-2, more 
Stim of CD137 
increases CD8+ 
infiltration 
Activation, proliferation, 
prolonged survival 
Gotsman et al. 2007[25]; Bu et al. 
2011[26]; Watts 2005[2] 
Definitions are in the introductory list of abbreviations. 
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4 ATHEROSCLEROSIS 
4.1 ON THE AGE OF ATHEROSCLEROSIS 
Atherosclerosis is a smoldering chronic inflammatory disease that develops over decades. For 
thousands of years, atherosclerotic disease has affected large and medium size arteries. 
Findings in ancient Egyptian mummies, and in mummies from Alaska, reveal atherosclerotic 
lesions similar to lesions of the modern human being [27-31]. This suggests that 
atherosclerosis not only depends on modern lifestyle, but also has a complex pathophysiology 
involving ancient physiological mechanisms, such as inflammation. 
Inflammation was introduced 25 AD by Celsus who described the features of an 
inflammatory reaction as: rubor (redness), calor (heat), dolor (pain), and tumor (swelling) 
[32]. Later, another feature, Functio laesa, was added to the other four describing the loss of 
normal function of the inflamed tissue [33]. In the middle of the 19th century, Rudolf 
Virchow described the cellular pathology of the atherosclerotic lesions and claimed that 
inflammatory cells play a role in the pathophysiology [34]. Adding to the findings of 
Virchow more than a century ago, Nikolaj N. Anitschkow and Semen S. Chalatov published 
their experimental finding that a cholesterol rich fed to rabbits led to atherosclerosis [35]. 
Later, Anitschkow showed that atherosclerotic plaques consist not only of lipids but also 
inflammatory cells, including lymphocytes and macrophages [36] - the same observation as 
Virchow had done almost half a century earlier. The discovery of immune cells in 
atherosclerosis did not attain the same historical distinction as cholesterol, and atherosclerosis 
was later considered a product of hyperlipidemia, platelet accumulation, and shear stress, 
leading to endothelial damage, deposition of lipids, and smooth muscle cell proliferation [37]. 
Using immunohistochemical methods with monoclonal antibodies, Jonasson et al. observed 
activated immune cells within the atherosclerotic lesion in the mid 1980’s. They were able to 
clarify the cellular composition of the atherosclerotic plaque and expose the presence of 
macrophages and activated T cells. Their published report is a hallmark for modern 
atherosclerosis research [38].  
When considering atherosclerosis of the arterial wall in light of present evidence, there is an 
orchestrated interplay between different immune cells within the innate and adaptive immune 
system, and other cells that are immunologically active, but that traditionally not belong to 
the immune system, e.g. endothelial cells (EC) and smooth muscle cells (SMC) in the 
progressing lesion [39]. The subsequent studies of immunological mechanisms in 
atherosclerosis have revealed an intricate complexity in the pathogenesis in the 
atherosclerotic lesion. For example, the discoveries of toll-like receptors (TLR) in 
atherosclerosis [40] and different subsets of T- and B lymphocytes have deepened the 
knowledge on the mechanisms causing this chronic inflammation in the arterial wall [39]. 
There is ample evidence that the inflammatory activity is a key player in lesion development 
as well as in plaque rupture - the event responsible for most clinical manifestations of 
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cardiovascular disease [39, 41-46]. The development of atherosclerosis and its clinical 
manifestations is clearly a complex process that involves a sophisticated interplay between 
inherited host factors, lipid metabolism, inflammation, circulation physiology, coagulation, 
and probably a host of additional yet not fully recognized factors. 
4.2 ON THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS 
A normal healthy artery consists of three distinct layers (Figure 2): 1) the tunica intima with 
an endothelial monolayer resting on the basal membrane, and a few resident smooth muscle 
cells; 2) the tunica media composed of SMC and extra-cellular matrix, separated from the 
intima by the internal elastic lamina; and 3) the tunica adventitia containing loose connective 
tissue, mast cells, nerve endings and micro vessels, separated from the media by the external 
elastic lamina, [47]. 
4.2.1 Onset of atherosclerosis 
Atherosclerotic lesions start to develop early in life. Beginning as a fatty streak in the intimal 
layer of the arterial wall, low-density lipoprotein (LDL) containing cholesterol that has 
entered the subendothelial space of the vascular wall triggers an inflammatory response. The 
cellular components of the early fatty streak are macrophages, T cells, and mast cells, the 
latter two less numerous than macrophages [44] (Figure 2). Post-mortem investigations of 
prevalence of fatty streaks in 2 to 39 years old individuals have shown that practically all 
included subjects had fatty streaks in the aorta, and that approximately 50% of subjects aged 
between 2 to 15 years had fatty streaks in the coronary arteries. Eight percent of the 
investigated subjects at 2 to 15 years of age had plaques in the coronary arteries. The 
prevalence increased with age to 69% in subjects 26 to 39 years of age [48]. Previous studies 
of soldiers killed in battle during the Korean war show a similar pattern, with a prevalence of 
about three-quarters of soldiers with an average age of 22 years where evidence of coronary 
atherosclerotic disease was found. Of these, 15% had a luminal narrowing in one or more 
vessels ranging from 50% to complete occlusion [49]. Taken together, these studies show that 
a majority of the study participants had manifest atherosclerotic disease, and that virtually all 
had the early stages of atherosclerosis that could develop into advanced disease. 
4.2.2 Development of the atherosclerotic plaque 
An activated endothelium will express adhesion molecules, an important factor for 
atherosclerosis formation. These molecules recruit leukocytes to the developing lesion. 
Together with lipid depositions in the arterial wall, the recruited leukocytes start the 
development of an atherosclerotic plaque. Anatomical features, such as curvatures and 
branches of the arterial tree, form the basis of flow and different levels of shear stress on the 
endothelium. Reduced shear stress may lead to activation of the endothelium, [50, 51].  
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The dominant cell type recruited is monocytes that will differentiate into macrophages. Some 
macrophages will engulf modified cholesterol particles such as oxidized LDL, eventually 
developing into foam cells. Activated macrophages produce pro-inflammatory cytokines such 
as tumor necrosis factor (TNF), and interleukin-1β (IL-1β), thus contributing to the 
pro-inflammatory milieu in the developing atheroma [39]. Neutrophils are present at the early 
stages of lesion development, and have been suggested to play a role at sites of plaque 
erosion [52]. T cells and macrophages, and a few other inflammatory cells, such as mast cells 
and DC, accumulate in the forming atherosclerotic lesion. T cells play a central role in 
regulating the inflammatory milieu [39] (Figure 2). No single pivotal factor that continuously 
drives this non-resolving inflammation has been identified, but several factors have been 
proposed, e.g. endogenous parts of LDL [39, 53] and crystalized cholesterol [54]. The 
inflammatory activity in the lesion may result in production of cytokines and chemokines, 
such as IL-6 and monocyte chemoattractant protein 1 (MCP-1), and as a consequence, the 
recruitment of immune cells [55]. Subsequently, IL-6 production may lead to the synthesis 
and release of C-reactive protein (CRP) from the liver. Elevated CRP has been recognized as 
an independent risk factor for atherosclerosis [46].  
SMC produce collagen, which contributes to plaque stability. SMCs migrate from the tunica 
media, and SMCs from the intima proliferate, both contributing to the build-up of a fibrous 
cap enclosing the forming lesion. Beneath the fibrous cap, some of the cells die leaving 
debris and cholesterol that form the highly thrombogenic necrotic core. Large advanced 
lesions may also be supported by new microvessels, which facilitate a communication 
between the developing lesion and the patrolling immune cells [47] (Figure 2). 
4.2.3 The role of tunica media and tunica adventitia in atherosclerosis 
Most atherosclerosis research has focused on the intima and the formation of an 
atherosclerotic lesion within intima. However, the role of tunica media and tunica adventitia 
has gained increased attention. For example, vascular smooth muscle cells (VSMCs), the 
most abundant cell type of the tunica media, are capable of expressing TLRs [56] and are 
able to produce inflammatory cytokines such as IL-1, IL-6, and TGFβ [57]. Interestingly, the 
tunica media is sparsely infiltrated with leukocytes, suggesting an immunoprivileged site 
restricting the neointimal inflammation from spreading to the medial layers [58]. The 
outermost layer of the vessel is the tunica adventitia, which contains mast cells, DCs, 
lymphatic vessels, nerve endings, and late in the process tertiary lymphoid organs (TLO) 
[47]. Lymphatic vessels drain to lymph nodes, which provide a path for immune cells, e.g. 
APCs, to migrate to lymph nodes and present antigens from the lesion. This creates a 
foundation for immune responses towards antigens generated in the atherosclerotic lesion 
[47]. The atherosclerotic microvessels probably come from the adventitia, stretching into the 
inner layers of the vessel providing connections between the deep layers of the lesion and the 
circulation [47, 59]. TLOs develop at sites of non-resolving inflammation, and can be located 
in the tunica adventitia adjacent to atherosclerotic lesions. In the TLOs of the adventitia, 
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T cells and B cells interact with APC, and germinal centers are formed, emphasizing the 
potential role of TLO in lesion development [60].  
Taken together, available evidence points towards an interaction between all layers of the 
atherosclerotic artery as an important part of pathophysiology [47, 57]. 
4.2.4 Lipids 
LDL levels in blood correlate with the risk for cardiovascular disease, and the associated risk 
is synergistically amplified when increased in combination with elevated CRP [46]. The 
levels of LDL can be lowered in patients with treatment with hydroxymethyl coenzyme A 
reductase inhibitors (statins), and patients treated with statins have lower risk of 
cardiovascular events [61-63]. Although beneficial, statin treatment is not a sufficient 
treatment for atherosclerosis. The risk of adverse cardiovascular events in patients with 
advanced atherosclerotic lesions is still present, in spite of statin treatment [45]. However, 
widespread statin therapy have changed not only lipid profile, but may also have affected 
inflammatory features of the plaque, such as reduced macrophage content in carotid lesions 
[64-66]. In addition, the distribution of clinical manifestations of atherosclerosis may have 
shifted somewhat, but the cause of these changes is not fully known (see also section 4.2.5) 
[43]. 
High-density lipoproteins (HDL) are sometimes referred to as “the good cholesterol”. Indeed, 
low plasma levels of HDL have been recognized as a risk factor for cardiovascular disease 
(CVD) [67]. HDL particles can act as transporter proteins for cholesterol from the peripheral 
tissues. By unloading cholesterol from foam cells in the atherosclerotic lesion and transport it 
to the liver, HDL can decrease the lipid content in the atheroma. Furthermore, separately 
from its lipid-transporting role, HDL may also reduce inflammation [68]. In contrast, clinical 
trials targeting HDL has not shown significant benefits [61]. Thus, whether the decreased 
cardiovascular risk associated with increased HDL is related to a decreased lipid burden of 
the atheroma or reduced inflammation is yet unclear. 
4.2.5 Plaque rupture and plaque erosion 
Post-mortem studies show that about 70% of the fatal myocardial infarctions are due to 
plaque rupture with an intraluminal thrombus limiting blood flow [45, 69]. The remaining 
30% are assumed to be caused by plaque erosion [39, 45, 70]. Plaque rupture is the main 
cause of coronary thrombosis, and is more common in men than in women [71].  
Plaque rupture is defined as a structural defect in the fibrous cap of the atherosclerotic lesion 
separating the lipid-rich necrotic core from the blood stream [72]. The rupture will expose 
thrombogenic substances, such as tissue factor and lipids, to the blood stream. This will lead 
to a thrombus formation and subsequent impairment of the blood flow, either at the site of the 
rupture, or downstream in the vasculature by embolism [45, 73] (Figure 2). Atherosclerotic 
plaques associated with rupture are rich in lipids, poor in collagen, have thin fibrous caps, and 
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have abundant inflammation [43]. The exact mechanism triggering the rupture is not known, 
but intense inflammatory activity has been suggested [73]. 
Plaque erosion is defined as a plaque with loss of luminal endothelial cells with no structural 
defect is seen in the fibrous cap. The loss of endothelium exposes SMCs and proteoglycans to 
the blood stream leading to a thrombus formation. In addition, a plaque with endothelial 
dysfunction that leads to a thrombus formation is also defined as an eroded plaque, even if 
the ECs have not disappeared [72]. Plaques associated with erosion have different features 
compared to plaques associated with rupture. For example, plaques associated with erosion 
are rich in proteoglycans and glycosaminoglycans, have fewer inflammatory cells, and lack 
large lipid pools [70].  
In carotid atherosclerosis, the ratio between rupture and erosion as the cause of symptoms is 
similar to the ratio in coronary arteries [74]. However, in patients presenting with transitory 
ischemic attack (TIA), the ratio of erosion is higher [75]. Furthermore, in women under 50 
years of age that suffered from sudden coronary death, the rupture rate is lower in favor of 
erosion [45, 71]. Given the trajectory of morphological changes over the last decades [65], 
endothelial erosion may become an even more prominent issue in the future. 
Interestingly, recent evidence indicates that plaques with thin caps and high lipid content 
rarely rupture to cause clinical events [76]. This suggests that clinical disease is not caused by 
a single lesion that is easily identifiable prior to clinical symptoms, and that there are several 
plaques capable of causing clinical disease [77, 78]. This notion was supported by a study 
using intravascular ultrasound where approximately 5% of plaques with thin caps ruptured 
during a follow-up period of 3.4 years [76]. 
One study of carotid atherosclerosis shows a morphological shift towards smaller lesions in 
recent time [65]. Van Lameren et al. reported that not only did the plaque size decrease, but 
there was also a decreased frequency of plaques with large lipid cores, and high macrophage 
content. Furthermore, the occurrence of plaque thrombosis and degree of plaque calcification 
also decreased. High macrophage content and large lipid pools are characteristics of complex 
atheroma, and the decline of these features are consistent with observed decline in the 
incidence of ST elevation myocardial infarction (STEMI) vs. non-ST elevation myocardial 
infarction (NSTEMI) ratio [65], and the observed decline in stroke [79, 80]. These 
observations indicate a decrease in plaques prone to rupture, and a relative increase of plaque 
erosions [43]. Of note, erosion is more common in women, in patients with diabetes, and in 
elderly patients, and this coincides with the observed demographic changes in patients with 
acute coronary syndrome (ACS) [43]. It has been suggested that these changes in plaque 
composition over time, and possibly the pathophysiology of atherothrombotic disease, has 
been driven by the use of statins [43], but several other factors also need to be considered, for 
example changes is smoking and dietary habits [81]. 
The introduction of statins together with new ways of examination, such as intraluminal 
ultrasound, has revealed both a new face of the disease, and new ways of evaluating disease 
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in patients. Bearing this in mind, however, one should not forget that plaque rupture still 
accounts for a vast majority of fatal myocardial infarctions and inflammation intensity is still 
of great importance. Thus, the change in atherosclerotic features adds to the complexity of the 
disease and demands a new research approach, including not only the classical features of 
plaque rupture, but also methods detecting erosion as a mechanism of atherothrombosis. 
4.2.6 Inflammation and plaque physiology 
Abundant evidence indicates that local inflammation in the vascular wall plays an important 
role for precipitation of clinical events, plaque rupture, erosion, and thrombus formation. 
Immune responses are commonly initiated by signals in pattern recognition receptors, 
including TLRs, nucleotide-binding oligomerization domain-like receptors (NLRs), and 
others. Pattern recognition receptors are expressed within atherosclerotic plaques [40]. 
Interestingly, atherosclerotic ECs express TLR2 that may recognize pathogen associated 
molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs). TLR2 is 
primarily expressed in SMC-rich plaques and receptor binding may promote EC activation 
and/or apoptosis of the EC, processes that may lead to detachment of the EC and subsequent 
exposure of thrombogenic substances to the blood stream [52]. Other mechanisms 
influencing EC adherence, such as mechanical stimuli promoting vascular SMC production 
of proteoglycans and hyaluronan [82], may act in concert or independent of TLR2 [70]. 
Increased local levels of repair-associated cytokines such as TGFβ stimulate SMC to produce 
collagen that contributes to mechanical cap strength [83, 84]. Conversely, plaque 
inflammation leads to increased local levels of IFNγ, which inhibits SMC proliferation and 
collagen production and degradation [84-86].  
4.2.6.1 T cells in atherosclerosis 
Several subtypes of T cells have been implicated in atherosclerosis (Table 1). T cells are an 
essential part of the atherosclerotic disease, and the interaction between several cells, 
including different T cell subsets, B cells, and innate immune cells, within the atherosclerotic 
lesion decides the fate of the atherosclerotic lesion [39]. 
Since the inflammatory response in atherosclerosis is orchestrated by T cell activity, the 
costimulation necessary for activation of T cells is important. Several costimulatory 
molecules have been implicated in atherosclerosis. For example, CD40L deficiency reduces 
atherosclerosis in apolipoprotein E deficient (Apoe-/-) mice [87], and OX40L deficiency in 
Apoe-/- also reduces atherosclerosis [12]. Interestingly, CD40 deficiency in Apoe-/- mice 
reduced atherosclerosis [87], but not in low-density lipoprotein (LDL) receptor deficient 
(Ldlr-/-) mice [88], indicating a complex function for costimulatory molecules in 
atherosclerosis. 
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4.2.6.1.1 T helper 1 cells 
T helper 1 (Th1) cells are CD4+ and are present in atherosclerosis [39]. The signature 
cytokine of Th1 T cells is IFNγ. In mice, IFNγ promotes atherosclerosis, and this is also 
shown in human arteries transplanted into mice [73, 89]. Conversely, atherosclerosis in 
Ifnγ-/- mice is reduced compared to Ifnγ+/+ control mice [90]. Several cells within the 
atherosclerotic lesion are capable of producing IFNγ, including macrophages [73] and natural 
killer T (NKT) cells [91]. IFNγ serves as one signal of the classical macrophage activation 
[92]. In addition, IFNγ promotes upregulation of MHC class II, and inhibits SMC 
proliferation and production of collagen [84, 85], features that has been associated with 
plaques rupture [93]. 
4.2.6.1.2 T helper 2 cells 
CD4+ T helper 2 cells are present in human and murine atherosclerosis but the frequency 
compared to other T cell subsets is unclear [39, 94]. Th2 cells produce cytokines such as 
IL-4, IL-5, IL-10, and IL-13. Several of the Th2 cytokines have been suggested to be 
atheroprotective. For example IL-10, a cytokine also produced by Treg, reduces 
atherosclerosis [95] as does IL-5 [96]. In contrast, deficiency of the Th2 signature cytokine 
IL-4 has been shown to decrease atherosclerosis [97, 98]. Therefore, the net effect of Th2 
activation on atherosclerosis is unclear. 
4.2.6.1.3 Cytotoxic T cells 
Cytotoxic CD8+ T cells usually occur in low numbers in experimental murine atherosclerosis 
[41]. In human atherosclerosis, CD3+ lymphocytes account for about 10% of cells and CD8+ 
T cells account for about a third of the CD3+ cells, a proportion similar to peripheral blood 
[73]. Interestingly, a recent study by van Dijk et al. show a dynamic pattern with higher 
CD8+/CD4+ ratio in early stages of human atherosclerosis, a ratio that will be almost 
equalized in later stages [94]. Cytotoxic T cells exert their effect by inducing apoptosis via 
Fas ligand (FasL, CD95L), or by release of proteolytic, or pore-forming enzymes.  
4.2.6.1.4 Regulatory T cells 
Treg are present in atherosclerotic lesions, but the levels of Treg are low in human plaques 
[22, 94]. Tregs have been shown to have a significant impact on atherosclerosis in murine 
models [23]. The signature cytokines of Tregs are TGFβ and IL-10. Apoe-/- mice expressing a 
dominant negative TGFβ receptor II in T cells, thereby disrupting TGFβ signaling, has 
increased atherosclerotic lesion size, increased IFNγ mRNA levels in the aorta, and increased 
macrophage and T-cell content in lesions [99]. Induction of Tregs decreases IFNγ levels and 
reduces lesion size [24]. This notion is supported by a study in Apoe-/- mice that showed that 
depletion of Treg by anti-CD25 antibodies increases atherosclerosis and increases 
macrophage and T cell content in lesions. The effect was abolished in mice lacking TGF-βII 
receptor in T cells, indicating that TGFβ is essential for Treg effects in atherosclerosis [100]. 
Bone marrow transfer of IL-10+/+ cells to irradiated Ldlr-/- x IL-10-/- mice resulted in 
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increased lesion development [101], supporting an important role for IL-10 in the 
pathogenesis of atherosclerosis. In light of this, Treg remain an attractive target for immune 
manipulation in atherosclerosis treatment. 
4.2.6.1.5 Th17 cells  
Th17 cells are present in atherosclerosis and have been suggested to be both pro-atherogenic 
and atheroprotective [97]. Recent evidence suggest that TGFβ and IL-6, derived from the 
atherosclerotic plaques, can skew T-cell differentiation towards a Th17 cell phenotype in 
draining lymph nodes of the aorta, and that an increase in IL-17A can promote features 
associated with plaque stability [21]. 
4.2.6.2 B cells  
Splenectomized Apoe-/- mice develop aggravated disease compared to controls, and transfer 
of B cells from Apoe-/- mice rescue and protect against disease [102]. In contrast, recent data 
indicate that depletion of B cells using anti-CD20 antibodies reduced lesions size in 
Apoe-/- and Ldlr-/- mice [103]. The role of B cells in atherosclerosis is clearly complex, and 
one can speculate that the distribution of antibody production in terms of specificity and 
isotype might be important. Germline-coded antibodies have been suggested to be 
atheroprotective, but recent data suggest that these antibodies lack protective function, and 
the role of B cells in atherosclerosis is not completely clear [104]. In addition to antibody 
production, B cells can function as APC and secrete cytokines, functions that has been 
implicated in the pathogenesis of atherosclerosis [105]. 
4.2.6.3 Innate immunity in atherosclerosis 
Granulocytes are important cells in the host defense against pathogens and the most abundant 
leukocyte in the circulation. Neutrophil granulocytes are present in the early stages of the 
development of the atherosclerotic lesion, and have also been observed in advanced stage 
lesions [106]. Neutrophils express TLR2, and Tlr2 deficiency in Ldlr-/- mice decreases 
atherosclerosis [107]. TLR2 on ECs stimulated by neutrophils aggravates EC stress and may 
induce apoptosis, suggesting that neutrophils may provide a mechanism for plaque erosion 
[52]. Eosinophils are attracted to sites of inflammation by chemoattractants, such as CCL2, a 
chemoattractant expressed in atherosclerosis. Detecting eosinophils in atherosclerosis has 
been challenging, maybe due to short half-life. The contribution of eosinophils to 
atherosclerosis remains unclear [96]. 
Mast cells are present in atherosclerotic lesions from an early stage [44]. In healthy arteries, 
few mast cells are located in the adventitial layers. In atherosclerosis, mast cells accumulate 
in the adventitia and under the luminal endothelium, indicating that recruitment of mast cells 
occur from both the luminal side and from microvessels to the atheroma [108]. Through the 
release of proteases and cytokines such as IL-6 and IFNγ, mast cells are believed to 
contribute to the inflammatory milieu in the plaque [109, 110]. 
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Macrophages derived from tissue-infiltrating monocytes are present at all stages of disease 
and constitute the major inflammatory cell type in the lesion [39, 44]. Monocytes patrol the 
arterial wall and migrate at sites as a response to chemokines, such as CCL-2 [111]. In 
atherosclerosis, mainly the LY6hi subset is recruited to the lesion, and monocytes then 
matures into macrophages or DCs. In addition, resident macrophages may also proliferate 
locally in the tissue [111]. Infiltration of monocytes is seen in early atherosclerosis and 
monocytes accumulate in the aortic root and thoracic aorta of Apoe-/- mice [96]. Macrophages 
in atherosclerosis are phagocytic cells that express TLRs [112], costimulatory molecules [6], 
and present antigens in a MHC class II restricted fashion to helper T cells. Activated 
macrophages secrete proteases and pro-inflammatory cytokines such as TNF and IL-1β, that 
contribute to increased inflammation and lesion development [96]. In atherosclerosis, both 
the classically activated macrophages induced by IFNγ, TNF, and lipopolysaccharide (LPS), 
and macrophages induced by other cytokines, such as IL-4 and IL-10 are abundant [113]. In 
addition, macrophages express costimulatory molecules such as CD80, CD86 [111] and 
CD137L [6]. When the macrophages die, they release lipids and tissue factor, both important 
for the pro-thrombotic features of the necrotic core [111]. 
Dendritic cells are professional APCs which are present in atherosclerotic lesions [114]. DCs 
communicate with the atherosclerotic lesion both through microvessels and by tissue 
migration in and around the atheroma. Upon antigen presentation to the adaptive immune 
cells, DC costimulate these cells, a process taking place in draining lymph nodes or in 
secondary lymphoid organs, and possibly also in tertiary lymphoid organs (TLO), potentially 
bringing T cell costimulation and adaptive immunity in very close proximity of 
atherosclerotic lesions [47] (Figure 2). 
4.2.7 Current clinical practice 
The anatomical characteristics of the vasculature are important determinants of the location 
of the atherosclerotic lesion. Typically, lesions develop at branches with turbulent flow, such 
as the carotid bifurcation. In contrast, sites with laminar flow are relatively resistant to early 
atherosclerosis development [51]. Although the flow itself is likely not responsible for lesion 
development, the hemodynamic activation of the endothelium is probably involved in the 
process leading to an atherosclerotic lesion [39, 51, 115, 116]. The location of the 
atherosclerotic lesion will affect the manifestation of the disease. For example, a plaque in the 
right coronary artery may affect sinus rhythm if blood flow to the sinoatrial node is disrupted, 
and a carotid plaque may embolize to the brain. 
Atherothrombosis in a coronary artery may impair blood flow and delivery of oxygen and 
nutrients to the heart. The pulsatile contracting myocardium has a high demand of both 
oxygen and nutrients as reflected by the low oxygen saturation in sinus coronaries of 
approximately 30% [117]. The lack of oxygen and nutrients will first lead to impaired 
regional contractility of the heart, which may be manifested as heart failure. Another 
sometimes devastating complication is cardiac arrhythmias. Death of cardiomyocytes will 
lead to the release of markers of cellular damage, such as troponins.  
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Treatment of a myocardial infarction is based on three cornerstones; 1) platelet inhibition to 
prevent additional thrombus formation; 2) decrease of oxygen demand to prevent additional 
cellular death; and 3) revascularization to restore blood flow, oxygen delivery, and delivery 
of nutrients to the myocardium.  
Rupture or erosion of a plaque in the carotid arteries may lead to a thromboembolic stroke, 
i.e. death of brain cells as a consequence of impaired blood flow in a vascular territory of the 
brain. The brain has a high oxygen and energy demand and is therefore very sensitive to any 
lack of blood supply. 
Treatment of manifest stroke is principally based on restoring blood flow to the affected parts 
of the brain. This can be achieved either by dissolving, or by removal, of the thrombus. In 
addition, anti-coagulant drugs are an important treatment to counteract new thrombus 
formation. 
Surgical removal of carotid atherosclerotic plaques is an established method for stroke 
prevention and was first done in the early 1950’s [118]. Carotid endarterecomies are not used 
as an acute treatment, but rather a preventive measure for patients at risk for stroke, such as 
patients that suffered from a transitory ischemic attack (TIA). Interestingly, Rothwell et al. 
reported a decrease in stroke incidence. In combination with the reported changes in carotid 
plaque morphology by van Lammeren et al. we need to consider if this is change in course of 
disease and mechanism, i.e. an increased proportion of erosion rather than rupture of carotid 
plaques [65, 80]. It is tempting to draw the conclusion that the changes in CVD presentation 
are due to treatment with statins. However, life-style changes and healthcare improvement 
may also affect outcome, and any connection with change in disease needs to be proven in 
studies.  
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5 TUMOR NECROSIS FACTOR SUPERFAMILY 
Receptors of the TNFRSF can be divided into two groups; 1) receptors with a death domain 
(DD, known as death receptors) that mediate apoptosis upon ligation, and 2) receptors 
interacting with TNF receptor associated factors (TRAF). TNFRSF are membrane bound, 
except two receptors always secreted as soluble proteins. Soluble forms of other TNFRSF, 
including CD137 (sCD137), are a result of cleavage or are generated by alternative 
splicing [119, 120].  
Ligation of members of the TNFRSF results in either 1) apoptosis (e.g. ligation by TNF, 
CD95L), 2) proliferation (e.g. ligation by TNF, CD137L, OX40L), 3) differentiation (e.g. 
ligation by TNF, RANKL) or cell survival (e.g. ligation by RANKL) [120]. Ligation of 
different TNFRSF has receptor-type unique cellular effects despite common molecules in the 
signaling pathways [120]. Ligation of receptors, interacting with TRAFs, leads to the 
recruitment of TRAFs to the cytoplasmic tail of the receptor (Figure 3). Six TRAFs has been 
described in mammals, TRAF1-6 [120].  
The molecule-specific responses of the different TNFSF/TNFRSF depend on a unique 
signature produced downstream of the ligation [2]. Furthermore, reverse signaling activating 
the ligand-expressing cell upon ligation of the receptor contributes to fine-tuning of responses 
[121]. This mechanism enables more plasticity of the immune response as it makes effector 
and stimulus codependent [121]. Reverse signaling can itself also change expression of 
costimulatory molecules. For example, ligation of OX40L on monocytes and DC by OX40 
increases expression of other costimulatory molecules such as CD40, CD80, and CD86 [121, 
122]. 
5.1 CD137 – REGULATION AND PATHOPHYSIOLOGY 
5.1.1 CD137 – Regulation of expression 
CD137 (alternative names 4-1BB, TNFRSF9) is a 28 kDa transmembrane receptor and the 
functional receptor is, like the ligand, trimerized on the cellular surface [123, 124]. Cells 
expressing CD137 are listed in table 2. CD137 is a CD28 independent costimulatory receptor 
of T cells [2]. CD137 is expressed on activated, but not on resting T cells [125]. Both CD4+ 
and CD8+ T cells express CD137, but stimulation of CD137 preferentially induces 
proliferation of CD8+ T cells [126]. Furthermore, CD137 can also be expressed on Treg, and 
ligation of CD137 on Treg results in proliferation [9, 127]. The onset of CD137 expression in 
T cells upon activation is very fast. This expression can be prolonged with continued antigen 
exposure. CD137 upregulation is dependent on mitogen-activated protein kinases (MAPK) 
pathways, and T cell receptor ligation dependent CD137 regulation involves nuclear factor κ-
light- chain enhancer of activated B cells (NFκB) and activating protein-1 (AP-1) (Figure 3) 
[128].  
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Table 2. Cells expressing CD137, CD137L, and OX40L. 
 
Definitions are in the introductory list of abbreviations. 
 
  
 
  
Cell type Comment Reference 
    
CD137 Effector T cells Expressed on activated T 
cells, mainly CD8+ 
Pollok et al. 1993[125]; 
Kwon et al. 1987[129] 
  Treg Constitutively expressed in 
mice, inducable in humans 
Goldstein et al. 2012[127]; 
Croft 2009[123] 
  NK cells Expressed upon activation Melero et al. 1998[130] 
  NKT cells Expressed upon activation Kim et al. 2008[131] 
  EC Expressed at sites of 
inflammation 
Drenkhard et al. 2007[132] 
  DC Variable expression Wilcox et al. 2002[133] 
  Follicular DC   Pauly et al. 2002[134] 
  Monocytes Induces activation Schwartz et al. 1995[135]; 
Kienzle et al. 2000[136] 
  B cells Promotes survival and 
proliferation 
Schwartz et al. 1995[135]; 
Zhang et al. 2010[137] 
  Mast cells Augments secretion of IgE 
and cytokines 
Nishimoto et al. 2005[138] 
  Eosinophils   Heinish et al. 2001[139] 
  Neutrophils Expression in circulating 
neutrophils 
Heinish et al. 2000[140] 
  SMC Variable expression Broll et al. 2001[141] 
    CD137L DC 
APC -Bidirectional activation 
Shao, Schwartz 2010[142]; 
Langstein et al. 1998[143] 
  B cells 
  Macrophages 
  Monocytes 
    OX40L DC 
APC -Bidirectional activation 
Croft 2009[123]; Lichtman 
2012[1]; Gerdes, Zirlik 
2011[144] 
  B cells 
  Macrophages 
  SMC   Wang et al. 2005[145] 
  EC   Nakano et al. 2010[12]; 
Wang et al. 2005[145] 
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Vascular SMC in tumor tissue express CD137 as shown by immunohistochemistry in a study 
by Broll et al., but the CD137 expression was variable between different tumor tissues [141]. 
Interestingly, CD137 deficient Apoe-/- mice show less apoptosis among vascular smooth 
muscle cells in the atherosclerotic lesions [146]. 
Ligation of CD40 by CD40L, molecules associated with increased inflammation in 
atherosclerosis [147], reduces the constitutive CD137 expression on DCs [148]. 
5.1.2 CD137 signal transduction 
Ligation of CD137 leads to recruitment of TRAF1 and TRAF2, both required for maximal 
MAPK and NFκB activation in T cells (Figure 3) [2]. TRAFs are adaptor molecules needed 
to link the activated receptor to the intracellular signaling pathways [123]. TRAF2 is the 
major contributor to the classical (i.e. canonical) NFκB pathway responsible for fast response 
to stress stimuli [149]. Human CD137 can also recruit TRAF3 [150]. The alternative (i.e. 
non-canonical) NFκB activation pathway is normally slower in response (hours), due to the 
need of new protein synthesis. This latter pathway is usually suppressed by TRAF2. These 
mechanisms are hitherto most extensively studied for CD40-CD40L interactions. In this 
system, upon ligation of CD40, TRAF2 and 3 will be degraded, promoting an increase of 
NFκB inducing kinase (NIK) and, as a consequence, increased NFκB activity through the 
alternative pathway [8, 149]. The function of CD137 in the alternative pathway is unclear. 
In summary, ligation of CD137 on T cells leads to TRAF-dependent NFκB activation and 
T cell expansion. 
 
 
  
Figure 3. CD137/CD137L signaling. A) Reverse signaling of the ligand (CD137L) activates the APC at the 
same time as the ligand crosslinks the receptor (CD137). The T cell receptor complex provides signal 1 and 
the costimulatory receptor (CD137) provides signal 2, both needed for activation of the T cell. B) Signal 
transduction of CD137 in T cells. 
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B
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5.1.3 Role of CD137 in experimental models of inflammatory diseases 
There is an abundance of evidence that ligation of CD137 using agonistic antibodies 
contributes to amelioration of disease, in several models of autoimmune diseases. 
Treatment with CD137-stimulating antibodies in models for Systemic Lupus Erythematosus 
(SLE) resulted in increased CD8+ counts, ameliorated lymphadenopathy and splenomegaly, 
depletion of specific B cell clones, and markedly prolonged survival in mice due to reduced 
levels of auto-reactive antibodies [14, 151]. Furthermore, Vinay et al. showed that an SLE 
model deficient in CD137 has increased manifestations of SLE and increased mortality, 
suggesting a role for CD137 in experimental SLE development [152]. Treatment with a 
CD137 stimulating antibody in a model for experimental autoimmune encephalitis (EAE) 
resulted in reduced induction of EAE, and inhibition of disease relapse [13]. In the collagen 
induced arthritis (CIA) model, a mouse model for rheumatoid arthritis, administration of 
CD137 stimulating antibody blocked disease development, induced protective memory, and 
suppressed established disease [153, 154]. In addition, in a model for allergic asthma, 
administration of CD137-stimulating antibodies decreased allergen hyper-responsiveness and 
production of allergen-specific IgE, or even ameliorated disease [155, 156], effects that were 
abolished in Cd137-/- mice [157]. 
Hence, the totality of the available evidence implicates an important role for CD137 in a 
number of experimental models of autoimmune and inflammatory diseases. Considering the 
important role of inflammation in atherosclerosis pathophysiology, there is reason to examine 
the evidence on CD137 in vascular disease. 
5.2 CD137 LIGAND – EXPRESSION AND FUNCTION 
CD137 ligand (CD137L) was first described by Pollok et al. as a co-regulator of B cells 
[158]. CD137L is mainly expressed on the cell surface on activated APCs, and is a 27 kDa 
transmembrane protein with an intracellular N-terminus and an extracellular C-terminus [119, 
142, 148]. In general CD137L expression is low. Under chronic inflammatory conditions, 
CD137L expression may be increased [159]. Interestingly, a feed-forward function has been 
suggested on both human and murine DC, where crosslinking of CD137L by CD137 
increases enhances expression of CD137L itself, CD40, CD80 and CD86 [142]. 
CD137L activates both human and murine bone marrow derived macrophages and promotes 
expression of ICAM-1, M-CSF, and pro-inflammatory cytokines, such as TNF, IL-6 and IL-
1β [142]. TLR4 activation induces CD137L expression, and endotoxin exposure of DCs 
promotes CD137L expression. Furthermore, a direct interaction between TLR4 and CD137L 
on the cell surface can promote TNF production in macrophages, indicating crosstalk 
between the innate and adaptive immunity [142, 160]. CD137L can be co-expressed with 
CD137 on activated murine and human T cells [161, 162], and exposure of human PBMC to 
either a CD137 decoy receptor, or antibodies targeting CD137L inhibits proliferation of 
T cells [142]. In addition, CD137L-stimulated DCs induce a stronger T cell response as 
supported by higher levels of IFNγ and increased proliferation [142]. 
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Taken together, there is a strong foundation for CD137L expression in inflammatory milieus, 
such as the atherosclerotic lesion. Ligation of CD137 by CD137L activates both the APC and 
the receptor-expressing cell by bidirectional signaling. 
5.2.1 Signal transduction and regulation of expression of CD137 ligand 
A trimeric CD137L cross-links CD137 (receptor), thereby initiating the effects described 
with the receptor activation [123]. Besides activating CD137, CD137L also transmit signals 
into the cell on which it is expressed upon crosslinking the receptor (Figure 3). This feature is 
shared with several members of TNFSF and is referred to as reverse signaling or, together 
with the receptor signal, as bidirectional signaling [142]. Cross-linking of CD137L expressed 
on APC activates MAPK pathways, leading to NFκB activation and induction of pro-
inflammatory cytokines, such as TNF, IL-1, IL-6, and IL-12 [123].  
5.3 OX40 LIGAND – EXPRESSION AND SIGNALING 
OX40 ligand (OX40L, alternative names: CD252, TNFSF4) is a 34 kDa glycosylated type 2 
transmembrane protein expressed on activated APCs and endothelial cells. As with other 
TNFSF, a trimeric set of OX40L molecules bind to trimerized OX40 molecules [12, 123]. 
OX40 (CD134, TNFRSF4) is mainly expressed on activated T cells [2, 144]. In general, 
stimulation of the OX40L/OX40 pathway leads to clonal expansion and is important for 
long-lasting T cells responses [123]. OX40L/OX40 signaling increases survival of both 
effector and memory T cells, and to play a role in several inflammatory diseases, such as 
EAE [144]. Interestingly, OX40L/OX40 signaling inhibits development and function of 
regulatory T cells [10]. Like CD137L, OX40L ligation activates the cell by bidirectional 
signaling via the MAPK pathways. Ligation of OX40L leads to expression of cytokines, such 
as TNF, IL-1, IL-6, and IL-12. Furthermore, activation of OX40L in combination with TLR 
stimulation can lead to proliferation of DC and B cells [123, 163]. 
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6 METHODOLOGICAL CONSIDERATIONS 
The methods used in this thesis are in many respects standard methods in the field of medical 
research. However, all methods have their inherent strengths and weaknesses that need to be 
taken into consideration when assessing study design, results and conclusions. 
6.1.1 Carotid lesions and control arteries 
Human carotid lesions used in the studies included in this thesis are from the biobank of 
Karolinska endarterectomies (BiKE) cohort of peroperatively obtained carotid lesions [164, 
165]. The plaques are from patients undergoing endarterectomy and plaques are handled and 
analyzed in a standardized manner to optimize for consistent quality of data. Patients in BiKE 
have lesions that are at an advanced stage of disease. Advanced lesions offer a unique 
opportunity to study late stage disease that is clinically relevant. When interpreting data from 
BiKE, disease stage needs to be taken into consideration since we are not comparing 
advanced lesions with lesions that would not be considered for surgery. The challenge of 
getting less advanced plaques is extremely hard, since benefits of surgery need to outweigh 
its risks and no one should be subjected to surgery without reasonable cause. The controls in 
the BiKE cohort are iliac arteries from organ donors and one aortic biopsy, all free from 
macroscopic atherosclerosis. An artery free from atherosclerosis normally contains very few 
infiltrating leukocytes and inflammatory activity is sparse. The renal arteries used as healthy 
arterial controls in this thesis were obtained from patients during nephrectomy due to kidney 
cancer. Macro and microscopic examination did not show any signs of vascular 
inflammation, but it is difficult to completely exclude that the pre-existing disease had some 
unknown effect on the artery. 
Taken together, the included carotid lesions serves a good purpose for atherosclerosis studies 
and lots of knowledge has been derived from studying atherosclerotic lesions from carotid 
endarterectomies. Compared to studies on coronary atherosclerosis, which is mostly done on 
post-mortem specimens, peroperatively obtained carotid biopsies are a unique source of 
minimally degraded material. However, efforts should be made to improve human specimens 
for research, and there must be a continuous assessment of validity. 
6.1.2 Human cohorts 
HapMap is an international effort to describe the genetic variations in humans. Several 
populations were included in the project and different international research groups analyzed 
genotypes of the included subjects. In our study, we use the population of 30 trios of Utah 
residents of northern and western European ancestry (CEU) [166]. The publically available 
data was merged with data on gene expression in lymphoblastoid cell lines of the same 
population where CD137 mRNA levels were measured [167, 168]. At the time of the 
analysis, the combined data set offered an innovative and unique way to study the links 
between genotypes and CD137 mRNA expression. We performed our analysis using the 
available material at the time and identified one SNP of interest for CD137 expression, 
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rs2453021 in CD137 [167]. This method does not describe protein expression, nor function 
or location, but offers a good opportunity for hypothesis generation for further investigation. 
CASTRO is a population based survey of a nested case-control design and includes 
participants enrolled in two health surveys in northern Sweden. Blood samples and basic 
clinical data, such as blood pressure and comorbidity, were obtained at baseline. Cases used 
in our study were defined as ischemic first stroke before 75 years of age. DNA from 393 
cases and 782 controls were available for analysis. 64 cases were excluded due to 
hemorrhagic stroke based on CT scan examinations, and 2 cases and 3 controls were 
excluded due to failed genotyping. CASTRO offers a unique opportunity to study genotype 
association with the incidence of stroke in a population based survey covering approximately 
96% of strokes in the populations studied [169].  
SAHLSIS is a Swedish study population of 600 patients with ischemic stroke and 600 
matched controls. The subjects that suffered from ischemic stroke were categorized into 
subtypes according to etiology, i.e. large-vessel disease, small-vessel disease, cardioembolic 
stroke, cryptogenic stroke (undetermined cause despite extensive examination), other 
determined cause (cause that was known but did not fit into the defined categories), or 
undetermined cause (>1 cause or brief determination). SAHLSIS offers an opportunity to 
replicate the investigation in the CASTRO material in a similar population. Of note, in the 
SAHLSIS population investigated here, 98 of 600 individuals suffered from cardioembolic 
stroke [170, 171]. This multiplicity of causes might possibly reduce the clinical impact of a 
genotype since its effect on cardioembolic disease and vascular atherothrombosis may differ 
significantly. This should be taken into account when interpreting the findings of this study. 
PROCARDIS is a European multicenter project that assembled a cohort that suffered from 
myocardial infarction or other acute coronary symptoms before 65 years of age [172]. The 
cohort has been genotyped by using either the Illumina Human 1M or 610K quad arrays and 
imputed to 1,000 genomes (CEU panel August 2009 release), and the subjects are 
phenotyped with clinical and biochemical data. In our analysis, imputed data was used for the 
study of CD137 since the investigated SNP (rs2453021) was not represented on the original 
array. Imputed data can be considered an accepted surrogate for testing the original SNP. In 
our study, there was no significant association between the imputed genotype data and 
coronary artery disease (CAD). Thus, the present results on imputed associations regarding 
the studied SNP (rs2453021) should be further investigated as more precise genetic data 
becomes available. 
IMPROVE is a European multicenter study cohort of approximately 3400 individuals that 
had at least three risk factors for CVD but were free of CVD at enrollment [173]. The carotid 
arteries of the participants were examined using ultrasound and clinical laboratory data was 
collected. Participants were followed up during 36 months for evaluation of clinical 
cardiovascular events. The IMPROVE cohort represents a unique opportunity to study how 
genetic variations affect patients in relation to CVD. Ultrasound is a highly user-dependent 
technique where continuous assessment of findings is executed in real time by the examiner. 
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To minimize the inter-examiner-differences and inherent methodological variability, the 
IMPROVE cohort investigators use standardized examination protocols. Ultrasound 
examinations of the carotid arteries were performed using a frequency of 7-8 MHz and this 
frequency gives an axial resolution of 0.385mm and lateral resolution of 0.500mm. The study 
measured intima media thickness (IMT), which can be used as a marker of subclinical 
atherosclerosis. Importantly, IMT, i.e. a thickening of the innermost layer of the artery, is not 
necessarily correlated to an advanced atherosclerotic disease stage, but reveals a 
measurement of local atherosclerotic burden. In this way, measurement of IMT offers an 
opportunity to investigate development of atherosclerosis before onset of clinical CVD [174-
176].  
6.2 EXPERIMENTAL ATHEROSCLEROSIS 
6.2.1 Apolipoprotein E deficient mice and the inducible plaque rupture 
model 
To study mechanisms of atherosclerosis, a good model for disease is needed due to the 
obvious difficulties of setting up experiments in human subjects. Normally, mice do not 
develop atherosclerosis if not challenged with lipid rich diets for long periods of time. In this 
context, development of mouse models has been pivotal for atherosclerosis research [51]. 
Genetically modified mice with altered lipid metabolism are widely used in atherosclerotic 
research [39]. The mouse model in this thesis is the Apoe-/- mouse [177-179]. The lesions that 
develop in Apoe-/- mice share several features with human atherosclerotic lesions, for 
example the inflammatory phenotype and development of necrotic core in older mice [177, 
180]. Rupture can occur in older mice, but rupture frequency is low, and the long time span 
makes the use of old mice difficult in investigations of plaque rupture mechanisms [146]. 
This has led to development of new models of plaque rupture based on the Apoe-/- mouse, 
where the carotid artery is partially ligated for atherosclerosis formation, and a conical cuff is 
placed around the ligated artery after 4 weeks to induce plaque rupture [181, 182]. This 
inducible plaque rupture model is one tool for the study of the rupture process. The exact 
mechanism inducing the rupture in this model is not fully understood, but changes in shear 
stress due to increased flow rate when narrowing the lumen has been suggested [181]. In 
humans, there is strong evidence pointing towards that increased inflammatory activity is 
important for plaque rupture [39, 45, 46]. In the inducible plaque rupture model, mice are at a 
relative young age at the time of euthanasia and the impact of inflammation on rupture is not 
clear [179, 182, 183]. In addition, recent evidence indicate that plaque erosion becomes 
increasingly important [43] and this model needs to be evaluated in this respect [70]. 
Although this model of plaque rupture does not perfectly replicate what likely is the most 
common pathogenesis of atherothrombosis in humans, it is useful to investigate particular 
aspects of vascular damage and atherothrombosis.  
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6.2.2 The 2A antibody 
The CD137-stimulating antibody 2A used in the work of this thesis is a well-established 
antibody that has been used in other studies of inflammatory diseases [13]. When CD137 was 
targeted in models of inflammatory disease, several studies showed amelioration and 
sometimes reversal of established disease [13, 14, 154, 155]. The antibodies in the present 
studies were injected intraperitoneally and the antibodies are reasonably subsequently taken 
up into the circulation. The kinetics of the 2A antibody is not known, and optimal dose in the 
model has not been determined. The anatomical distribution of effects of the antibody is also 
not fully known and it is, therefore, currently unclear in which compartments the 2A effect is 
most pronounced and important. In our experiments, the antibody had the expected effects 
with increased proliferation and increased inflammation, i.e. replicating the immunological 
phenotype we set out to study. 
6.3 ANALYSES 
6.3.1 Semiquantitative real-time PCR (Taqman) and expression arrays 
The measurement of mRNA levels in this thesis was performed using semiquantitative real 
time PCR (RT-PCR) (TaqMan) of target and reference transcripts, or gene arrays. Arrays 
offer a convenient platform for measurement of multiple molecule mRNA levels allowing for 
broad screening with a limited use of tissue. Since proteins are major performers of cellular 
functions, mRNA measurement is sometimes regarded as less informative. On the other 
hand, protein levels by themselves do not unequivocally predict function, efficacy, effect 
kinetics, and the influence of inhibitors and competition from other cellular processes. In light 
of this, measurement of mRNA levels does not provide a final answer about cellular 
functionality, but is a relevant source of information about changes in physiology and cellular 
function. 
6.3.2 Single nucleotide polymorphism’s – SNPs 
Single nucleotide polymorphisms (SNP) are variations in a single nucleotide at a specific 
position in the genome. Variations defined as SNPs usually occur in ~1% or more of the 
population. Identification of SNPs in individuals can be performed by analyzing their DNA 
by PCR based technology or specialized DNA microarrays. An association between the 
presence of a SNP and a particular disease in a population provides statistical support for a 
connection between the genotype and disease development. Importantly, this relationship 
denotes an association between a SNP in a gene locus and disease, and does not prove an 
association with a gene or protein. To determine causality between the nucleotide variation 
and disease development, further investigation is needed. Therefore, statistical associations of 
SNPs with disease alone must be interpreted caution, but are valuable for hypothesis 
generation. Using these genetic association data together with experimental studies with a 
pre-formed hypothesis can be a fruitful approach to generation of new knowledge and 
advance our understanding of disease mechanisms. 
  31 
The studies in this thesis analyzed genotypes and SNP using a hypothesis-driven approach, 
that is, a hypothesis was formulated based on the available data before the genomic data was 
queried and only one SNP was studied. Specifically, we and others first provided mechanistic 
data on TNFSF members in cardiovascular disease and the genetic regulation of CD137 in 
humans. Subsequently, hypotheses were formulated and tested in the available populations. 
6.3.3 Immunohistochemistry 
The basic principle used in immunohistochemistry is that primary antibodies bind to epitopes. 
Either a secondary antibody or another molecule that selectively detects the primary antibody 
subsequently detects antibody binding. Color is then used to analyze localization of the bound 
antibody. Immunohistochemistry can be used in combination with direct staining of tissue 
components (e.g. Sudan IV staining fat) for morphological visualization. These methods are 
used on a routine basis in clinical settings and has been a huge success in atherosclerotic 
research, maybe best exemplified by the discovery of inflammation in the atherosclerotic 
lesion [38]. The method has several advantages and weaknesses. The most striking advantage 
is the possibility to detect morphology and cellular location. Co-localization and physical 
proximity for cellular interaction can be revealed. The methods require highly specific 
antibodies. This is especially important when detecting molecules that have not been 
thoroughly investigated (methodologically) and when investigating molecules in complex 
tissues like atherosclerotic lesions where necrosis, fat and debris offer lots of unspecific false 
positive binding sites for the antibody. Results must therefore be evaluated with great care 
and sufficient control measures must be taken to evaluate the results. This includes relevant 
isotype controls, unstained sections and a thoughtful strategy. Perhaps most important of all, 
the results must be interpreted in the context and should be supported by other methods i.e. 
immunohistochemistry alone does often not offer sufficient evidence of expression, co-
localization, and interactions. 
6.4 CONCLUSION OF METHODS 
To study a chronic life threatening disease, one would ideally study the disease in real time 
with a perfectly matched control and no confounding factors. One of the most obvious 
problems with this approach in atherosclerosis is that most of the study objects would outlive 
the researcher. Therefore, to advance knowledge and provide a basis for clinical protocols, 
we need to push our methodological knowledge forward and handle the inherited weaknesses 
of the methods available. The researcher has a huge advantage in the possibility to test a 
hypothesis, evaluate the result, and refine the experiment. This way, models and methods can 
improve continuously, and we can add new results to the bank of knowledge. Since 
atherosclerosis research ultimately strives to treat human disease, it is of great importance to 
evaluate all experimental data in the context of human using the available methods and 
samples. 
The methods used in this thesis are by no means perfect, but they are well-established and 
recognized so that others can evaluate our results for transparence and sharing of knowledge.  
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7 EVIDENCE ON COSTIMULATION IN 
ATHEROSCLEROSIS FROM OUR EXPERIMENTAL 
STUDIES 
The papers included in this thesis explore aspects of CD137 and OX40L in human and 
murine atherosclerosis. The focus of papers I, III and IV is CD137, and the focus of paper II 
is OX40L. Together these studies show that CD137 and OX40L are expressed in 
atherosclerosis and influence atherosclerosis pathophysiology. 
7.1 CD137; PAPER I, III, IV 
In an exploratory study with the aim to identify important molecules in the vascular 
inflammatory response, we incubated human arteries with endotoxin and measured effects on 
mRNA levels using Affymetrix gene array. This experiment identified CD137 as one of the 
most up-regulated genes (data not shown). The finding was surprising, because CD137 has 
mostly been considered a costimulatory molecule expressed on T cells, but since T cells are 
very rare in normal healthy arteries, we conjectured that the observed increased CD137 
mRNA levels might have another cellular origin, and possibly play an unexpected role in the 
vascular inflammatory response and atherosclerosis. The findings caught our interest for 
many reasons. First, CD137, previously identified as a potent costimulatory molecule of 
T cells and also expressed by several other cells, had been shown to influence inflammatory 
diseases in mouse models of SLE and RA in a remarkable way with amelioration of disease 
and reports of regression of established disease [13, 154]. Furthermore, the non-resolving 
inflammation that is a hallmark of atherosclerosis has important features in common with 
other inflammatory diseases such as RA. The key role of T cells for orchestrating the 
pathogenic immune response in atherosclerosis further supported the interest in this CD28 
independent T cell costimulator – especially now considering the reports on reduced CD28 
expression in the elderly [184], a population in which cardiovascular disease is the major 
contributor to morbidity and mortality. Accordingly, we decided to investigate CD137 in 
human and murine atherosclerosis. 
In human atherosclerotic arteries, CD137 mRNA levels were higher than in normal arteries, 
and incubation with LPS significantly increased CD137 mRNA levels. Paper I provided the 
first evidence of CD137 expression in human atherosclerosis. This study also discovered that 
CD137 expression was not limited to T cells in the atherosclerotic lesions, but it was also 
expressed on endothelial cells. There was no detectable expression of CD137 on any other 
cell type, which was somewhat surprising since CD137 is known to be expressed on several 
cell types (Table 2), of which the majority are present in atherosclerotic lesion. However, 
identification of the cell types was primarily done with immunofluorescence and the 
observed expression morphologically led us to investigate co-expression with markers of 
T cells and EC. Therefore, it is possible that other cell types expressing CD137 might be 
identified in atherosclerosis. In human atherosclerosis, CD137L staining co-localizes with 
CD68, indicating expression on macrophages [6, 185]. One of the most abundant cell types in 
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atherosclerosis is macrophages, suggesting an anatomical basis for CD137/CD137L 
interaction in lesions [6, 39, 42]. In patients with acute atherothrombotic stroke, Yu et al. 
observed increased levels of both CD137L expressed on circulating monocytes, and soluble 
CD137L (sCD137L) [186]. These results do not necessarily reflect the expression in 
atherosclerotic lesions, but higher levels of circulating sCD137L and membrane bound 
CD137L provides a foundation for increased CD137-CD137L crosslinking in these patients, 
although the conjectures about potential clinical effects on human atherosclerosis are yet 
distinctly speculative. Accordingly, in a series of subsequent experiments, we next asked 
whether activation of CD137 in experimental models had effects on vascular inflammation 
and atherosclerosis.  
In vitro, CD137 mRNA levels were increased in response to inflammatory cytokines in 
cultured human umbilical vein endothelial cells (HUVEC) and aortic smooth muscle cells 
(AoSMC). We also observed that stimulation of CD137 using a trimerized recombinant 
CD137 ligand (trCD137L) promoted surface expression of vascular cellular adhesion 
molecule-1 (VCAM-1) and intracellular adhesion molecule-1 (ICAM-1) in HUVEC. In 
cultured AoSMC, stimulation of CD137 with trCD137L inhibited AoSMC proliferation, an 
effect that was suppressed by the addition of the non-stimulating rCD137L monomer known 
to block ligand activation of CD137, thereby functioning as an antagonist. All this supported 
a role for CD137 in human atherosclerosis where the inflammatory milieu induces CD137 
expression. In light of these observations, we proposed that the effects of CD137 activation 
might promote recruitment of inflammatory cells and increased plaque inflammation. 
In patients with CVD, increased CD4+CD28null T cells correlate with an increase in CRP and 
proinflammatory cytokines in peripheral blood [187-189]. This T cell subset does not appear 
in mouse models of atherosclerosis and is therefore not studied in these models. Interestingly, 
the specific subset of CD4+CD28null T cells expresses high levels of CD137 and OX40 in 
patients with CVD, and these cells infiltrate atherosclerotic plaques. Furthermore, these 
CD137 expressing CD4+CD28null T cells can change to a cytotoxic phenotype expressing 
perforin (CD161) [190, 191]. In vitro, the same subset of cells kill ECs, a process increased 
by CRP in a dose dependent manner [192], and the cytotoxic activity of CD4+CD28null T cells 
in PBMC from patients with ACS can be activated or blocked by stimulation or blockade of 
CD137 respectively, supporting a possible role for CD137 in vascular damage [190, 191]. 
Interestingly, patients with ACS show increased plasma levels of soluble CD137 (sCD137), 
and levels correlate with increased troponin I, a marker for cardiac muscle injury [193], but 
the value of CD137 as a circulating biomarker is yet uncertain. 
To further deepen our understanding of CD137 pathophysiology, we choose to study the 
effects of CD137 on atherosclerosis in vivo, and we turned to the hypercholesterolemic 
Apoe-/- mouse model of atherosclerosis. CD137 mRNA levels were 10-fold higher in aortas 
of Apoe-/- mice compared to wild type C57BL/6 mice used as a reference. Following injection 
of the CD137 agonistic antibody 2A in Apoe-/- mice, we observed an inflammatory phenotype 
as evidenced by increased mRNA levels of TNF, IFNγ, IL-1β, and ICAM-1 in the aorta. In 
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atherosclerotic lesions of the 2A treated mice, we observed an increased expression of CD3 
and I-Ab. We also observed an infiltration of CD8+ cells in the lesions. This is interesting 
since cytotoxic CD8+ cells are rare in murine experimental atherosclerosis [4], but not 
uncommon in biopsies from human atherosclerotic lesions [38]. Moreover, Jeon et al. 
subsequently found that absence of CD137 in hypercholesterolemic mice resulted in 
decreased atherosclerosis and reduced inflammatory activity [185]. Furthermore, very old 
(>60 weeks of age) CD137 deficient hypercholesterolemic Apoe-/- (Apoe-/- x Cd137-/-) mice 
had less atherosclerosis and reduced plaque rupture frequency compared to Apoe-/- mice of 
the same age [146], indicating a role for CD137 in plaque rupture. The mechanism for this 
inflammatory change in atherosclerosis has not been fully elucidated. In other models of 
inflammatory diseases, other investigators have observed that ligation of CD137 on Th17 
T cells inhibits generation of more Th17 cells, favoring Treg. This is a suggested mechanism 
for the beneficial effects of CD137 activation in experimental some models of autoimmune 
diseases [20]. Interestingly, our observations suggest that other effects of CD137 activation 
may dominate in the pathogenesis of vascular inflammation, but the Th17/Treg ratio in our 
experimental was not investigated.  
After establishing that CD137 and its natural ligand were present in atherosclerosis, and that 
stimulation of CD137 aggravated atherosclerosis in a mouse model, we became interested in 
studying CD137 in human atherosclerosis further. Therefore, we decided to investigate if 
genotype influences CD137 expression and, if so, if that identified genotype is associated 
with CVD. In Paper III, we discovered that the minor T allele of SNP rs2453021 was 
associated with decreased CD137 mRNA expression in immortalized lymphocytes in 
HapMap. The difference was significant in males, but only reached borderline significance in 
females. The selection of the rs2453021 SNP was done after analyzing the available SNPs 
and their effects on CD137 mRNA levels in the HapMap cohort in combination with an 
expression analysis of the same cohort [166, 168]. Based on our previous findings, and the 
results of the analysis, the SNP with a clear significant effect on CD137 expression was 
selected. We did not analyze the other available SNPs further in this study. The choice of 
studying CD137 genotypes was strictly hypothesis driven based on our previous results of 
CD137 in atherosclerosis. The findings of associations between the selected rs2453021 
genotype should be considered in light of this basic premise. 
We proceeded to investigate if presence of the minor allele of rs2453021 was associated with 
signs of cardiovascular disease. To this end, we queried a number of human cohorts. We 
turned to the IMPROVE cohort of more than 3400 patients with at least three risk factors for 
cardiovascular disease, but no clinical symptoms of CVD at enrollment. In the common 
carotid artery of participants in the IMPROVE cohort, presence of the minor allele of 
rs2453021was associated with an increased intima media thickness (IMT) at baseline and at 
30 months follow-up. There was no significant association between rs2453021 and 
progression of IMT at the 30 months follow-up. When men and women were analyzed 
separately, the minor T-allele of rs2453021 was associated with higher mean IMT in men, 
but not in women, and with higher maximum IMT in women, but not in men. At the 36-
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month follow-up of the IMPROVE cohort, prospective data on incident clinical events was 
analyzed. A total of 190 subjects suffered from one event or more during the 36 months. 
There were no significant associations with myocardial infarctions, stroke, or peripheral 
vascular disease when analyzed separately or all together. However, the minor T allele of 
rs2453021 was associated with increased risk for non-cardiac events. The choice of grouping 
the non-cardiac events was based on the number of clinical events during the follow-up and 
the need for statistical power. We observed non-significant trends for cerebrovascular and 
peripheral events and future follow-up studies in this cohort are warranted to clarify these 
trends. Of note, we observed that the minor T-allele of rs2453021 was associated with 
vascular events (all) in men, but not in women. This is interesting since other studies of 
TNFSF, e.g. OX40L, have shown differences between sexes in associations and CVD [145]. 
There was a significant difference in the CD137 mRNA levels between men and women. The 
underlying mechanism behind these differences is currently unknown. The minor T allele of 
rs2453021 was associated with the presence of plaque, defined as maximum IMT >1.5 mm, 
in the common carotid artery. This difference was abolished when men and women were 
analyzed separately, possibly due to loss of statistical power. 
These results raised the question of potential associations between rs2453021 and clinical 
manifestations of CVD, and the PROCARDIS and WTCCC cohorts of more than 13000 
cases and controls were analyzed for associations between rs2453021 minor T allele and 
CVD. There was no association between the minor T allele of rs2453021 and the incidence of 
myocardial infarction or CAD in the 13029 cases and controls of the PROCARDIS cohort 
together with WTCCC controls.  
With the findings of CD137 in human atherosclerosis, the effects of CD137 stimulation in 
murine models of atherosclerosis, and the associations between the rs2453021 genotype and 
clinical disease in mind, the next step was to study the effects of CD137 on plaque rupture, 
considered the key event behind most clinical manifestations of CVD [43, 69]. To proceed, 
we turned to a murine model of inducible plaque rupture in Paper IV. We first confirmed 
that CD137 and CD137L mRNA levels are higher in atherosclerotic lesions compared to 
controls in both human and murine carotid atherosclerosis. In humans, we now compared the 
CD137 and CD137L mRNA levels between men and women, and between symptomatic and 
asymptomatic patients. There were no differences in CD137 or CD137L mRNA levels 
between symptomatic and asymptomatic patients, nor between men and women. In 
Apoe-/- mice, CD137 and CD137L mRNA levels were higher in ruptured carotid lesions than 
in non-ruptured. We also observed that mRNA levels of TNF, IFNγ, IL-1β, and MMP9 were 
elevated in ruptured murine carotid lesions compared to non-ruptured. Our previous in vitro 
data on human AoSMC and HUVEC showed that CD137 mRNA levels were higher in 
response to stimulation with inflammatory cytokines. If higher CD137 mRNA levels in the 
ruptured murine carotid plaques are induced by the inflammatory cytokines, or if the 
increased inflammatory milieu is caused by increased CD137 signaling remains unclear and 
needs to be addressed in a future study. 
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We also observed that in vivo treatment of Apoe-/- mice with the CD137 agonist 2A, increased 
the proportion of CD8+ and a decreased proportion of CD4+ splenocytes compared to IgG2a 
treated controls. We also observed that blood count of 2A treated mice were increased in 
granulocytes, proportion of monocytes, and frequency of mice with detectable eosinophils, 
compared to IgG2a treated controls. Furthermore, the proportion of circulating CD8+ cells 
and the CD8/CD4 ratio were increased in 2A treated mice compared to IgG2a controls. These 
findings are in line with previously observed effects by 2A treatment on CD8+ cells [6, 13, 
154]. We also observed that activation of CD137 with the agonistic antibody 2A resulted in 
significantly higher mRNA levels of TNF, IFNγ, and IL-10 in the abdominal aorta. No 
significant effect on the levels of IL-1β, IL-5, IL-6, or TGFβ by the treatment was detected. 
These are expected effects of 2A treatment and the observations support that the integrity and 
administration of 2A was adequate. 
To study the aortic atherosclerosis development in the experimental plaque rupture model, 
i.e. at an early disease time point in Apoe-/- mice, the thoracic aorta was pinned and stained. 
There was no significant difference in the atherosclerotic area between 2A and IgG2a treated 
mice as determined by oil-red-O staining. Importantly, the stained area in both groups was 
very low and ranged from 2-4%. It is very difficult to detect significant differences in disease 
development with this method in vessels that show this low fraction of stained area. Hence, 
we refrain from drawing conclusions about the 2A effect on atherosclerosis in this model at 
this time point.  
To investigate the effects of CD137 stimulation on plaque rupture frequency, we used a 
mouse model where the right carotid artery was partially ligated and a subsequent placement 
over the ligated artery in Apoe-/- mice. Arteries were ligated at 12 weeks of age and the cuff 
was surgically placed at 16 weeks of age. Four days after cuff placement, mice were 
euthanized. At harvest, plaques were scored using visual inspection and, in select individuals, 
evaluated with immunohistochemical stainings. There was no significant difference in plaque 
rupture frequency between 2A and IgG2a treated mice in this study. This was an unexpected 
finding since previous results indicated increased atherosclerosis and inflammation following 
CD137 stimulation, and the 2A treatment in the present study showed the expected effects on 
the other analyzed tissues and blood. However, the model used in this study is based on an 
incomplete carotid ligation to induce an atherosclerotic lesion, and a subsequent placement of 
a conical cuff around the ligated artery to induce rupture. The exact mechanism responsible 
for the rupture in this model is not fully known, but increased shear stress has been suggested 
[181, 182]. The contribution of inflammation on plaque rupture in this model is not fully 
known, but it is conceivable that there may be a difference in the mechanistic details of the 
pathophysiology leading to plaque rupture in this model compared to the process in a plaque 
that has developed under a long period of time. This speculation requires further experimental 
studies for proper evaluation. 
Interestingly, we observed a non-significant trend towards less rupture in the 2A treated 
group. Since the exact role and mechanism of CD137 in atherosclerosis is not known, we 
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speculate that this observation may be a result of the plaque dynamics and development 
during the very short time frame of atherosclerosis and rupture mechanisms in this model. In 
previous studies, we have demonstrated CD137 expression in human atherosclerosis and that 
a genotype was associated with increased risk for non-cardiac vascular events [6, 167]. The 
associated increase in non-cardiac vascular events in the previous study (Paper III) may not 
be due to plaque rupture, but plaque erosion. If and how erosion occurs in the used plaque 
rupture model in the present study (Paper IV) is not clear [51]. 
CD137 and CD137L mRNA levels are higher in atherosclerotic lesions compared to controls 
in both human and mice. In humans, there was no difference in terms of CD137 and CD137L 
mRNA levels between symptomatic and asymptomatic patients. In mice, there was a 
significant difference where both CD137 and CD137L mRNA levels were significantly 
higher in ruptured compared to non-ruptured carotid lesions. The observed difference 
between murine and human CD137 and CD137L expression patterns may suggest that there 
are differences in the mechanisms of disease. In humans, not all symptomatic patients suffer 
from rupture of the carotid plaques. Plaque erosion accounts for approximately one third of 
symptomatic carotid lesions [43, 45]. Atrial fibrillation is a frequent source of embolization to 
the brain and subsequent stroke and this needs to be considered when evaluating the study 
results. In the examined cohort, all patients that had undergone endarterectomy had advanced 
lesions that had developed over decades. In the examined murine plaques, CD137 mRNA 
levels were higher in ruptured vs. non-ruptured plaques. These plaques were thoroughly 
characterized with immunohistochemistry according to rupture/non-rupture, which might 
increase the precision of the results. The interpretation of the findings implicates a role for 
CD137 in atherosclerosis, and the exact function of CD137 in plaque rupture and plaque 
erosion needs further investigation. 
7.2 OX40L; PAPER II 
Several members of the TNFSF have been investigated in atherosclerosis [144]. OX40L 
(TNFSF4) is mainly expressed on APC and the natural ligand for OX40. OX40L/OX40 
signaling is important for T cell clonal expansion and memory development [2] and, 
importantly, OX40L/OX40 signaling dampens Treg response [10], all effects that have been 
coupled to increased murine atherosclerosis. Interestingly, murine Treg constitutively express 
OX40 and CD137, but expression of these molecules are inducible in human Treg [123]. In 
experimental atherosclerosis, lack of OX40/OX40L signaling decreases atherosclerosis in 
Apoe-/- mice [12], and disruption of OX40/OX40L signaling with a neutralizing antibody 
decreases atherosclerosis in Ldlr-/- mice [194]. Mice with targeted mutations in Ox40L 
(Tnfsf4) have smaller lesions and mice with overexpression of Ox40L had larger lesions than 
controls. In humans, the minor allele of rs3850641 in OX40L was associated with increased 
risk for myocardial infarction in women [145] and this led us to investigate if the same 
genotype, i.e. rs3850641, was associated with increased risk for stroke. In Paper II, we 
investigate the expression of OX40L in human atherosclerosis, and the association between 
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the minor allele of rs3850641 SNP and risk for stroke in two independent Swedish patient 
cohorts. 
OX40L was expressed in human atherosclerotic lesions. In carotid lesions of the BiKE 
cohort, OX40L mRNA levels were higher compared to healthy control arteries. 
Immunohistochemical stainings showed OX40L expression in plaques and 
immunofluorescent stainings demonstrated that OX40L expression co-localized with CD68, 
α-actin and von Willebrand Factor (vWF) in human plaques. The co-localization with vWF 
indicates expression on EC. Interestingly, the OX40L expression on EC was only noted in the 
intra-lesional part of the microvessels in the plaques. The importance of this observation is 
not clear, but the role of the microvessels has gained recognition and provides an anatomical 
foundation for communication between the deep layers of the atherosclerotic lesion and the 
blood stream. EC has been suggested to express OX40L constitutively [195]. In our study, we 
did not observe any expression of OX40L on EC facing the carotid lumen. Interestingly, 
Apoe-/- x Ox40L-/- mice develop less microvessels [12]. In Apoe-/- mice, OX40L expression 
has been shown on EC, SMC and macrophages in atherosclerotic lesions [145]. Since our 
previous findings of CD137 on EC in atherosclerosis revealed a heterogeneous expression, 
this may also be true for OX40L. Considering the constitutive expression of OX40L on EC 
previously reported by Mestas et al. [195], the lack of observed staining on EC might be a 
result of down-regulation. In cultured HUVEC, OX40L was induced by TNF stimulation, but 
not by LPS, suggesting a different response to stimuli compared to CD137. However, the 
lack of OX40L expression on EC facing the carotid lumen in this study is interesting since 
we show that OX40L mRNA levels are higher in EC after TNF stimulation, a cytokine that is 
expressed in atherosclerosis. The finding of OX40L expression on EC on atherosclerotic 
microvessels suggests that the milieu in the atherosclerotic plaque may vary at different 
locations within the plaque, and that this may influence OX40L expression. This finding also 
indicates that several mechanisms may be involved in controlling OX40L expression by EC 
in atherosclerosis.  
Since the minor allele of rs3850641 in OX40L (TNFSF4) had been associated with increased 
risk for myocardial infarction in women, we proceeded to investigate the influence of 
rs3850641 and risk for stroke. The rs3850641 did not significantly influence OX40L mRNA 
levels in 130 patients in the BiKE cohort, neither when all patients were analyzed, nor when 
men and women were analyzed separately. We also investigated the associations and need for 
surgery. There was no association between the minor allele of rs3850641 and the need for 
carotid endarterectomy when comparing patients in BiKE with matched controls neither 
when analyzing all patients, nor when men and women were analyzed separately. There were 
no significant associations of rs3850641with levels of atherosclerosis-associated systemic 
risk factors white blood cell count, HbA1c, CRP, cholesterol or triglycerides in the BiKE 
cohort. 
To investigate the associations between the minor allele of rs3850641 and the risk for stroke, 
we turned to clinical cohorts and replicated similar investigation in two independent Swedish 
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cohorts, SAHLSIS and CASTRO. There were no significant association of rs3850641 
genotype and risk for stroke in any of the separate cohorts, nor when women and men were 
analyzed separately. To further increase sample size and statistical power, we pooled the 
samples from CASTRO and SAHLSIS and observed similar results. The pooled sample size 
used in this study was 2300 individuals, approximately two thirds of the sample size used in 
the study by Wang et al., and may be insufficient for detection of and increased risk for 
stroke. However, our study was powered to detect an odds ratio of ≥1.25 with 80% power. 
Hence, based on these findings, a strong effect on the investigated genotype on the risk for 
stroke is unlikely.  
Hemodynamic forces and natural curvatures of the vasculature results in different flow and 
shear stress on the endothelium [51]. These differences in part dictates the sites of 
atherosclerosis development together with recognized risk factors, such as serum lipids and 
oxidative stress [51]. Differences in shear stress affect the expression of at least 100 genes, of 
which approximately two-thirds are up regulated and one-third is down regulated [196]. 
Thus, due to different anatomical locations and vessel anatomy in the carotid vs. coronary 
circulation, it is possible that the observed association between rs3850641 and risk for 
myocardial infarction in women by Wang et al. was associated with changes in a vascular 
segment that show a different gene expression pattern and physiology than carotid plaques. 
Taken together, our data show expression of OX40L in human atherosclerosis, but show no 
association between the presence of the minor allele of rs3850641 and increased risk for 
stroke. Although both myocardial infarction and stroke are commonly caused by 
atherosclerotic disease, the diseases at different locations may not be the same. We conclude 
that the effect of TNFSF members in atherosclerosis may differ with the anatomy and local 
physiology of the arterial tree. Further studies are warranted to elucidate the detailed 
mechanisms of TNFSF member influence on atherosclerotic disease. 
In our genetic studies of OX40L and CD137, there was a discrepancy in the results on 
myocardial infarction and stroke. While the reason for this is yet not entirely clear, it 
interesting to note that carotid atherosclerosis differs from the coronary atherosclerosis. For 
example, severity of stenosis strongly predicts future events in carotid, but not in coronary 
atherosclerosis [197]. In carotid atherothrombosis, a thrombus is rarely present at the luminal 
plaque erosion or rupture, and if present, it is usually small. The bigger vessel size and higher 
volume flow rates may contribute to both the differences in plaque morphology and 
embolization downstream [74]. Although not the same, coronary and carotid atherosclerosis 
shares many features, such as basic structures and infiltration of macrophages and 
lymphocytes [43, 45, 65, 76]. 
7.3 A ROLE FOR CD137 AND OX40L IN CLINICAL MEDICINE? 
Although there has been an improvement in care of patients with myocardial infarctions and 
stroke, this is still a main cause of death worldwide [198, 199], and there is a strong need for 
improved treatments. CD137 and OX40L play a role in experimental atherosclerosis and may 
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act as markers for severe carotid and coronary disease in humans [186, 193]. Pre-clinical 
studies on members of the TNFRSF/TNFSF have shown promising results, both in tumor 
biology and in CVD, suggesting that inhibition or stimulation of the TNFRSF/TNFSF could 
be a potential target for treatment of disease [147] (https://clinicaltrials.gov). Clinical trials, 
although promising, have revealed several problems that are not yet solved. For example, 
targeting TNFSF5 (CD154, CD40 ligand) was promising in murine models, but resulted in 
increased thrombosis due to expression on platelets [200]. In spite of this, the severity of the 
diseases, and potential benefits of manipulation of molecules of the TNFRSF/TNFSF, still 
drives development of new treatments targeting these molecules [4, 8, 201]. However, if the 
mechanistic details of CD137 and OX40 involvement in CVD are known, it is conceivable to 
use pharmacological means to manipulate their activity in efforts to prevent atherothrombotic 
events. 
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8 PERSPECTIVES 
8.1 IMPORTANCE OF MOLECULAR BIOLOGY – THE NEED FOR NEW TOOLS 
In general, we as scientists, are obliged to use a reductionist approach i.e. we choose to take 
out several factors influencing the investigated process to refine the effect of the particular 
mechanism or process we are studying. Nobel laureate Thomas Lindahl described how he 
could not accept the difference of the observed and expected results, a notion that led him to 
the discoveries of the DNA-repair mechanisms. One conclusion of this is that we constantly 
need to question all our results, methods and conceptions about biology, and develop new 
tools for investigation. Furthermore, as long as we get correct observations, the data we 
collect today will be valid over time, but the interpretation may change. For example, if we 
shook a rabbit 400 years ago, and measured heart rate, the result would be the same as if we 
shook a rabbit the same way today. The difference is our understanding of the process. 
The complex human atherosclerotic disease takes decades to a lifetime for full development, 
and experimental models where a hypothesis can be tested are probably the best ways for 
studies of the disease. The challenge is then to interpret the obtained data, and translate the 
results into human disease or physiology, a process that hopefully leads to better 
understanding and treatment of human disease. 
8.2 WE DO GET BETTER! 
The clinical use of TNF-inhibitors has changed clinical picture of several inflammatory 
diseases, and revolutionized the clinical outcomes for many patients. Unfortunately, not all 
patients are relieved from their symptoms, and there are side effects with the treatments in 
clinical use. Therefore, we need to continue developing new concepts for treatment, for 
example by exploring nerve stimulation for immunological manipulation. 
The quest for new treatments involves several methods, all with their inherent strengths and 
weaknesses, all used by the scientist to overcome an almost endless list of obstacles. 
Hopefully, the giant collective efforts put in to those methods by thousands of brilliant 
scientists will generate new approaches on how to diagnose and treat disease in new and 
better ways. 
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9 CONCLUSIONS 
 
Conclusions from the studies in this thesis are that 
 
• CD137 is expressed in advanced human atherosclerosis and activation of CD137 
aggravates atherosclerosis in hypercholesterolemic mice 
 
• a specific genotype influences CD137 expression and this variant is associated with 
the incidence of vascular disease 
 
• activation of CD137 aggravates inflammation, but not plaque rupture frequency, in an 
experimental plaque rupture model 
 
• OX40L is expressed on EC in microvessels in human atherosclerotic leisons, but the 
investigated OX40L genotype was not linked to an increased risk for stroke 
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